急性心力衰竭胸腔穿刺随机对照试验
TAP-IT 多中心随机对照试验纳入 135 例急性心衰伴中等以上胸腔积液患者,比较 upfront 超声引导胸腔穿刺置管引流联合标准药物治疗与单纯标准药物治疗。结果显示两组 90 天内院外存活天数、90 天全因死亡率和住院时长均无差异,研究期间胸腔穿刺主要并发症发生率为 1%。
要点
- 急性心衰伴胸腔积液患者 upfront 胸腔穿刺未增加 90 天院外存活天数。
- 两组 90 天全因死亡率和住院时长均无差异。
- 研究期间胸腔穿刺主要并发症发生率为 1%。
核心结论
- 对于急性心衰伴胸腔积液患者,upfront 常规胸腔穿刺联合标准药物治疗未增加 90 天院外存活天数、未降低全因死亡率、未缩短住院时长。
研究设计与样本
- 多中心、非盲、随机对照试验,于 2021 年 8 月 31 日至 2024 年 3 月 22 日开展。
- 纳入急性心衰、左心室射血分数 ≤45% 且胸腔积液不可忽略的患者,排除积液超过半胸三分之二的 Very large effusions。
- 135 例患者按 1:1 随机分配至 upfront 超声引导胸腔穿刺置管引流联合标准药物治疗组(n=68)或单纯标准药物治疗组(n=67)。
- 主要结局为 90 天内院外存活天数;关键次要结局包括住院时长和 90 天全因死亡率;所有结局按意向性治疗原则分析。
主要发现
- 胸腔穿刺组 90 天内院外存活天数中位数为 84 天(77; 86),对照组为 82 天(73; 86),P=0.42。
- 两组死亡率均为 13%,生存概率无差异(P=0.90)。
- index admission 住院时长无差异:对照组中位数 5 天(3; 8),胸腔穿刺组中位数 5 天(3; 7),P=0.69。
- 研究期间实施的胸腔穿刺中主要并发症发生率为 1%。
临床怎么用
- 对于急性心衰伴中等以上胸腔积液患者,不应以增加 90 天院外存活天数、降低全因死亡率或缩短住院时长為目的常规 upfront 行胸腔穿刺。
- 研究期间胸腔穿刺主要并发症发生率为 1%,可作为操作风险参考。
局限性
- 研究为非盲设计。
- 排除了积液超过半胸三分之二的患者,结论不适用于 Very large effusions 人群。
- 样本量 135 例,作者指出当前发现为未来研究奠定基础,需进一步研究确认结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion-Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion. METHODS: This multicenter, unblinded, randomized controlled trial, conducted between August 31, 2021, and March 22, 2024, included patients with acute heart failure, left ventricular ejection fraction ≤45%, and non-negligible pleural effusion. Patients with very large effusions (more than two-thirds of the hemithorax) were excluded. Participants were randomly assigned 1:1 to upfront ultrasound-guided pleural pigtail catheter thoracentesis in addition to standard medical therapy or standard medical therapy alone. The primary outcome was days alive out of the hospital over the following 90 days; key secondary outcomes included length of admission and 90-day all-cause mortality. All outcomes were analyzed according to the intention-to-treat principle. RESULTS: A total of 135 patients (median age, 81 years [25th; 75th percentile, 75; 83]; 33% female; median left ventricular ejection fraction, 25% [25th; 75th percentile, 20%; 35%]) were randomized to either thoracentesis (n=68) or standard medical therapy (n=67). The thoracentesis group had a median of 84 days (77; 86) alive out of the hospital over the following 90 days compared with 82 days (73; 86) in the control group (P=0.42). The mortality rate was 13% in both groups, with no difference in survival probability (P=0.90). There were no differences in the duration of the index admission (control group median, 5 days [3; 8]; thoracentesis group median, 5 days [3; 7], P=0.69). Major complications occurred in 1% of thoracenteses performed during the study period. CONCLUSIONS: For patients with acute heart failure and pleural effusion, a strategy of upfront routine thoracentesis in addition to standard medical therapy did not increase days alive out of the hospital for 90 days, all-cause mortality, or duration of index admission. The current findings lay the groundwork for future research to confirm the results. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05017753.
引用
- Glargaard, Thomsen, Tuxen, et al. A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure. Circulation. 2025. PMID: 40166829. doi:10.1161/CIRCULATIONAHA.124.073521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。